Galectin Therapeutics Inc (GALT)

Currency in USD
3.570
-0.190(-5.05%)
Closed·
3.720+0.150(+4.20%)
·
GALT Scorecard
Full Analysis
Stock has taken a big hit over the last week
GALT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.5603.839
52 wk Range
0.7264.410
Key Statistics
Prev. Close
3.76
Open
3.79
Day's Range
3.56-3.839
52 wk Range
0.726-4.41
Volume
186.79K
Average Volume (3m)
644.03K
1-Year Change
53.88%
Book Value / Share
-1.89
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GALT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.000
Upside
+68.07%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Galectin Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Galectin Therapeutics Inc Company Profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Compare GALT to Peers and Sector

Metrics to compare
GALT
Peers
Sector
Relationship
P/E Ratio
−5.7x−3.2x−0.5x
PEG Ratio
−0.310.010.00
Price/Book
−1.9x1.9x2.6x
Price / LTM Sales
-8.6x3.3x
Upside (Analyst Target)
68.1%191.5%40.1%
Fair Value Upside
Unlock0.9%5.1%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 6.000
(+68.07% Upside)

Earnings

Latest Release
Aug 14, 2025
EPS / Forecast
-0.12 / -0.19
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

GALT Income Statement

People Also Watch

7.110
AMPX
-4.44%
21.81
SRPT
+7.44%
57.81
BMNR
-4.37%
5.56
REPL
+3.93%
3.860
ONDS
-1.78%

FAQ

What Stock Exchange Does Galectin Trade On?

Galectin is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Galectin?

The stock symbol for Galectin is "GALT."

What Is the Galectin Market Cap?

As of today, Galectin market cap is 228.70M.

What Is Galectin's Earnings Per Share (TTM)?

The Galectin EPS (TTM) is -0.64.

When Is the Next Galectin Earnings Date?

Galectin will release its next earnings report on 16 Nov 2025.

From a Technical Analysis Perspective, Is GALT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Galectin Stock Split?

Galectin has split 1 times.

How Many Employees Does Galectin Have?

Galectin has 15 employees.

What is the current trading status of Galectin (GALT)?

As of 17 Aug 2025, Galectin (GALT) is trading at a price of 3.57, with a previous close of 3.76. The stock has fluctuated within a day range of 3.56 to 3.84, while its 52-week range spans from 0.73 to 4.41.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.